While international financing for TB has grown since 2002, it remains a paltry sum compared with the vast amounts of money channeled to other infectious diseases, such as HIV and AIDS.

By bridging the gaps that divide cancer, immunology, and microbiology, researchers may yet find creative and affordable ways to address the growing problem of drug-resistant tuberculosis.

In the new world of intensifying budget competition -- flat global health budgets, a widening post-2015 agenda, growing demand to address other non-communicable diseases -- TB is very vulnerable to becoming even more lost.

Stocks of medicines for drug-resistant tuberculosis are insufficient, and further shortages – leading to more tuberculosis and more drug resistance – are expected.

The European region has special challenges to face: high MDR and XDR-TB rates, lengthy hospital stays, and the need for changes in health, human rights policies including decriminalization, real civil society and community engagement.

Central TB Division (CTD) organised the Joint Monitoring Mission (JMM) in April 2015 along with the World Health Organisation country office to review the functioning of the Revised National TB Control Programme (RNTCP) of India.

The TB CAB and TAG restate their request to Johns Hopkins University to allow representatives of TB-affected communities to comment on the terms of any agreement with Sequella before it is finalized.

New MSF report surveying lay counsellor policies across eight countries highlights major weaknesses for adherence support.

Despite the critical need for increased TB resources, donor funding for TB decreased by nearly 10% in 2014.

Latest annual review on HIV, HCV and TB drugs, diagnostics, vaccines, preventive technologies, research toward a cure, and immune-based and gene therapies in development.